Navigation Links
Drugs.com Releases Q2 Sales for Top 100 U.S. Prescription Drugs: Humira Climbs into Top 5 and Posts Double-Digit Growth
Date:8/14/2013

NEW YORK, Aug. 14, 2013 /PRNewswire/ -- Drugs.com, the leading online clinical drug resource, today released second quarter 2013 U.S. prescription sales data for the top 100 drugs. Since Q2 2012, Otuska's antipsychotic Abilify and AstraZeneca's acid reducer Nexium have held either the number one or two spot in top dollar sales. This quarter, both agents continue to maintain their stronghold; each posts close to $1.5 billion in sales. Humira, AbbVie's key tumor necrosis factor (TNF) blocker, climbs three notches and sees a double-digit gain for the quarter.

(Photo: http://photos.prnewswire.com/prnh/20130814/PH63256-a )
(Photo: http://photos.prnewswire.com/prnh/20130814/PH63256-b )

Top Five Drugs by Sales, Q2 2013Drug NameSales ($000)% Change (previousquarter)Abilify

$1,597,913

+4.70%Nexium

$1,454,048

-0.34%Humira

$1,341,759

+10.22%Cymbalta

$1,338,912

+3.24%Crestor

$1,290,913

-0.37%The move of Humira into the top five shifts both Eli Lilly's Cymbalta, and AstraZeneca's Crestor down one position. Cymbalta, which reaped over $4.4 billion in 2012 U.S. sales, goes off patent this December.

Top Five Sales Gains, Q2 2013Drug NameGain ($000)% Change (previousquarter)Humira

$124,407

+10.22%doxycycline

$89,309

+46.22%Enbrel

$72,681

+6.76%Abilify

$71,685

+4.70%Epogen

$47,324

+9.40%Not only does Humira re-enter the top five drugs by sales, it also comes in at the number one spot in terms of sales growth. Enbrel, another TNF blocker, returns to positive growth after a slight drop in Q1. Abilify and Epogen round out the fourth and fifth spots in quarterly sales gains.

"The significant impact of TNF blockers on autoimmune disease activity is not only reflected in their varied indications such as rheumatoid arthritis, psoriasis and Crohn's disease, but also in their steady sales growth," said Philip Thornton, CEO of Drugs.com. "Since the second quarter of 2012, Humira, Enbrel, and Remicade have all placed in the top ten with revenues in the $1 billion range."

Top Five Sales Losses, Q2 2013 Drug NameLoss ($000)% Change (previousquarter)Avonex Pen

-$154,859

-45.78%Suboxone

-$78,819

-18.95%Advair Diskus

-$35,740

-2.80%Avonex

-$32,162

-9.51%modafinil

-$31,418

-14.37%Newer oral multiple sclerosis (MS) agents such as Novartis' Gilenya may now be impacting the use of injectable interferon such as Biogen Idec's Avonex, which loses significant growth this quarter. However, the news may not be all bad -- Biogen Idec also manufactures Tecfidera, the newest oral MS drug -- predicted to draw in over $3.5 billion in annual sales by 2017. Modafinil lost over 17 percent in sales gains in Q1 2013, and continues to slide this quarter.

Reckitt Benckiser's Suboxone for opiate dependence, now available only in the oral dissolvable film, drops close to $79 million. The sublingual tablet formulation of Suboxone, discontinued in March, can now be replaced with the generic version approved in February.

Detailed data on the top 100 drugs can be accessed at: http://www.drugs.com/stats/top100/sales

About Drugs.com
Drugs.com is the leading online drug information resource with over nine million unique visitors per month (ComScore, June 2013). Providing free, independent, peer-reviewed, and up-to-date information at both consumer and professional levels, Drugs.com empowers patients and caregivers to take charge of their health and be more informed than ever before. The site includes many interactive tools and mobile apps to assist consumers, healthcare professionals and researchers, such as personal medication records, a drug interaction checker, pill identification wizard, symptom checker, pharma sales statistics and more.

For more information, visit: http://www.drugs.com/

Media Inquiries:
Drugs.com Press Officer
Email
(718) 395 2473

Read more news from Drugs.com.

 


'/>"/>
SOURCE Drugs.com
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Drugs.com Releases Q1 Sales for Top 100 U.S. Drugs: Rough U.S Flu Season Boosts Numbers for Tamiflu
2. Drugs.com Launches iOS and Android Mobile App to Empower Patients and Providers Alike
3. Drugs.com Releases Q4 Sales for Top 100 U.S. Drugs
4. Drugs.com Releases Q3 Sales for Top 100 U.S. Drugs: Singulair Drops But Nexium and Abilify Remain the Leading Brands
5. Latest Drug Sales Data: Loss of Patent Protection Has Significant Effect, According to Drugs.com
6. Raritan Releases Dynamic Search User Interface on Amazon Web Services (AWS) Marketplace
7. Nutrastar Releases Second Quarter 2013 Results
8. Techne Corporation Releases Unaudited Fourth Quarter And Fiscal Year 2013 Results
9. Bekers Hospital Review Releases Report on State of Hospital Industry
10. Beckers Healthcare Releases Report on State of ASC Industry
11. Earnings Releases, Investment Plans, Commencement of Clinical Trials, and FDA Applications Brighten Outlook - Research Report on Bard, Centene, Exact Sciences, Ironwood, and Merrimack
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... New York , April 27, 2016 ... market report titled, "Skincare Devices Market - Global Industry ... 2023." According to the report, the global skincare devices ... and is anticipated to expand at a CAGR of ... Mn in 2023. Browse the full Skincare Devices ...
(Date:4/27/2016)...  Bayer Animal Health today announced that ... of Florida College of Veterinary Medicine, is the ... Award (BECA). Brittany was selected from entries representing ... of $70,000 in scholarship funds through the 2016 ... provided a total of $232,500 in scholarship awards ...
(Date:4/27/2016)... YORK , April 27, 2016 ... OASM ), a developer of a new generation ... announced positive overall survival results for Paclical/Apealea in ... of 789 patients with epithelial ovarian cancer. These ... groups: Paclical/Apealea in combination with carboplatin versus Taxol ...
Breaking Medicine Technology:
(Date:4/30/2016)... , ... April 30, 2016 , ... “Aging well is a challenge for all of us, but there are things ... Parul T. Kohli . “Research is showing more and more that there are simple, yet ... and disability as we age.” Top priorities Dr. Kohli’s recommends for her patients include;, ...
(Date:4/29/2016)... (PRWEB) , ... April 30, 2016 , ... ... engineer of patented products, announces the Pick Up Springboard, an automotive invention that ... Light Truck Manufacturing industry is worth $162 billion," says Scott Cooper, CEO and ...
(Date:4/29/2016)... Los Angeles, CA (PRWEB) , ... April 29, 2016 , ... ... Sarah Mirmelli, a mother and divorcee, shares her enthusiasm for Botox and lip injections, ... of the world famous youth oriented Coachella Valley Music and Arts Festival. The article ...
(Date:4/29/2016)... ... April 29, 2016 , ... Memorial Healthcare System Graduate ... Education (ACGME) that it has received accreditation for its residency program on Physical ... programs that Memorial is currently pursuing, including Pediatrics and Internal Medicine. This accreditation ...
(Date:4/29/2016)... ... April 29, 2016 , ... Our bodies are bombarded daily by environmental and ... with these stressors is to adopt a more healthful diet, but too many people ... a certified Holistic Nutritionist and the creator of the Newport Beach Cleanse and 14-Day ...
Breaking Medicine News(10 mins):